ERBB2 and neoplasm: Liposomes conjugated with cetuximab or trastuzumab, monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) or the human epidermal growth factor receptor 2 (HER2), respectively, reportedly enhanced the cytotoxicity of chemotherapeutic agents encapsulated in liposomes by increasing drug accumulation in targeted tumor tissues32–34.